Ekuinas makes maiden pharma investment


Ekuinas chief executive officer Syed Yasir Arafat Syed Abd Kadir (pic) said their entry into the healthcare and pharmaceutical space was timely as it looked to capitalise on global megatrends and demographic shifts amid the emergence of Covid-19.

KUALA LUMPUR: Ekuiti Nasional Bhd (Ekuinas) has made its maiden investment into the pharmaceutical industry with the acquisition of a controlling stake in Medispec (M) Sdn Bhd, based on an enterprise value of RM88.5mil.

The government-linked private equity fund management company said it was highly cognisant of the macro themes at play, which led to its entry into the industry.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Globetronics Partners with Taiwan's ChipMOS for Integrated Circuit Services
Hap Seng 3Q24 net profit soars nearly fourfold to RM193.11mil
Ringgit rises against US dollar for third consecutive day
KTI Landmark records RM230mil in sales, surpassing 2023 figures
MSM Malaysia’s 3Q net loss widens to RM49.7mil on forex loss
UEM Sunrise on track to hit RM1bil sales target
Perodua teams up with PETRONAS Dagangan and Gentari to improve services and EV support
Karex 1Q net profit tumbles 73.4% to RM1.4mil
DRB-Hicom focuses on digital transformation
FBM KLCI falls for third day, weighed down by Tenaga, YTL stocks

Others Also Read